

6-11-2020

## **Covid-19 Clinical Update 6/11/2020**

George Washington University

Follow this and additional works at: <https://hsrc.himmelfarb.gwu.edu/infectiousdiseaseupdates>

---

### **Recommended Citation**

George Washington University, "Covid-19 Clinical Update 6/11/2020" (2020). *GW Infectious Disease Updates*. Paper 14.

<https://hsrc.himmelfarb.gwu.edu/infectiousdiseaseupdates/14>

This Presentation is brought to you for free and open access by the GW Covid-19 Collection at Health Sciences Research Commons. It has been accepted for inclusion in GW Infectious Disease Updates by an authorized administrator of Health Sciences Research Commons. For more information, please contact [hsrc@gwu.edu](mailto:hsrc@gwu.edu).

1. EPIDEMIOLOGY

2. PATHOPHYSIOLOGY

3. TREATMENT

4. GW UPDATES

# COVID-19 UPDATE

HANA AKSELROD, MD, MPH

GW DIVISION OF INFECTIOUS DISEASES

6/11/2020



Genetically engineered cows are making human antibodies that neutralize SARS-CoV-2. SAB BIOTHERAPEUTICS

## This cow's antibodies could be the newest weapon against COVID-19

By Mitch Leslie | Jun. 5, 2020, 4:35 PM


Deaths

Cases

Daily counts

Cumulative

### New daily deaths reported in D.C., Maryland and Virginia



# Epidemiology

NEW DAILY CASES VS. 2 WEEKS AGO



## Tracking ReOpen DC

Phase 1 Reopening Metrics  
Thresholds needed to reach Phase 2

Data updated through: June 9, 2020

Not Achieved	Sustained decrease in cases in the community	10 out of 14 days	>
Coming Soon	Ability to contact trace new cases	Coming Soon	>
Achieved	Sustained low positivity rate	Below 15% for over 7 days	>
Achieved	Sustained low transmission rate	Below 1 for over 5 days	>
Not Achieved	Utilization of hospital beds	Below 80% for 11 out of 14 days	>
Coming Soon	Ability to contact trace close contacts	Coming Soon	>

The District of Columbia is closely monitoring key public health signs to guide reopening the District in a way that is safe, measured, data-driven, and sustainable.

The timing of when to remove or reinstate social (physical) distancing and other policies to slow the spread of COVID-19 will be determined in part by the reopening metrics shown here.

All metrics are subject to change based on evolving outbreak and data considerations.

Alaska

Maine

Vt.

N.H.

Wash.

Mont.

N.D.

Minn.

Wis.

Mich.

N.Y.

Mass.

R.I.

Idaho

Wyo.

S.D.

Iowa

Ill.

Ind.

Ohio

Pa.

N.J.

Conn.

Ore.

Nev.

Colo.

Neb.

Mo.

Ky.

W.Va.

Va.

Md.

Del.

Calif.

Utah

N.M.

Kan.

Ark.

Tenn.

N.C.

S.C.

D.C.

Ariz.

Okla.

La.

Miss.

Ala.

Ga.

Texas

Fla.

Hawaii


P.R.

# Cardiac Echography in COVID-19

- The most frequent abnormality in COVID-19 was RV dilation with or without dysfunction, likely due to pulmonary parenchymal or vascular disease.
  - 32% had a normal echocardiogram at baseline
  - RV dilatation and dysfunction observed in 39% of patients
  - LV diastolic dysfunction observed in 16%
  - LV systolic dysfunction observed in 10%
  - Patients with elevated troponin (20%) or worse clinical condition had worse RV function but not LV systolic function
  - Clinical deterioration occurred in 20% of patients
  - Femoral vein thrombosis (DVT) was diagnosed in 5 of 12 patients with RV failure.
- Overall, given the risk of infection spread, routine echocardiography for all patients with COVID-19 infection does not seem warranted.
- Among clinically deteriorating patients, an echocardiogram can be useful in identifying etiology of cardiac injury and possibly targeted treatment.



AMERICAN  
COLLEGE of  
CARDIOLOGY



## Cardiac Manifestations in COVID-19: Echocardiographic Study

Jun 09, 2020

Share via: [f](#) [t](#) [in](#) [e](#) [+](#) 42 [Print](#)

Authors:

Szekely Y, Lichter Y, Taieb P, et al.

# Retraction Watch: NEJM and Lancet Papers

THE LANCET

Log in Register

Access provided by GEORGE WASHINGTON UNIVERSITY

ARTICLES | ONLINE FIRST

PDF [1 MB] Figures

## RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Prof Mandeep R Mehra, MD, Sapan S Desai, MD, Prof Frank Ruschitzka, MD, Amit N Patel, MD

Published: May 22, 2020 • DOI: [https://doi.org/10.1016/S0140-6736\(20\)31180-6](https://doi.org/10.1016/S0140-6736(20)31180-6) Check for updates

- Summary
- Introduction
- Methods
- Results
- Discussion
- Supplementary Material
- References

## Summary

### Background

Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although generally safe when used for approved indications such as autoimmune disease or malaria, the safety and benefit of these treatment regimens are poorly evaluated in COVID-19.

The NEW ENGLAND JOURNAL of MEDICINE

SUBSCRIBE OR RENEW

IMAGES IN CLINICAL MEDICINE: Stargardt Juvenile Macular Degeneration

RECENTLY PUBLISHED Research in NEJM

ORIGINAL ARTICLE: Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria

ORIGINAL ARTICLE: Thrombectomy for Stroke in the Public Health Care System of Brazil

This article has been retracted.

ORIGINAL ARTICLE

## Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Mandeep R. Mehra, M.D., Sapan S. Desai, M.D., Ph.D., SreyRam Kuy, M.D., M.H.S., Timothy D. Henry, M.D., and Amit N. Patel, M.D.

Article Figures/Media Metrics

22 References 49 Citing Articles

### Abstract

**BACKGROUND**  
Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in this clinical context.

May 1, 2020  
DOI: 10.1056/NEJMoa2007621

**Related Articles**

**EDITORIAL** MAY 1, 2020  
Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19  
J.A. Jarcho and Others

**EDITORIAL** JUN 2, 2020  
[Expression of Concern: Mehra MR et al.](#)